Patents Assigned to Gilead Sciences, Inc.
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230242508
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Capsid inhibitors for the prevention of HIV
    Patent number: 11685728
    Abstract: The present disclosure provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of a compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 27, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elena Bekerman, Wade S. Blair, Anna Chiu, Tomas Cihlar, Dana J. Levine, Winston C. Tse, Stephen R. Yant, Jim X. Zheng
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11680064
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • Antiviral pyrazolopyridinone compounds
    Patent number: 11667613
    Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: June 6, 2023
    Assignees: Novartis AG, Gilead Sciences, Inc.
    Inventors: Zef Konst, Yipin Lu, Robert Joseph Moreau, Naomi Samadara Rajapaksa, Galen Shearn-Nance, David Charles Tully, Michael Robert Turner, Joseph Michael Young, Qian Zhao, Britton K. Corkey, Samuel E. Metobo
  • Methods for treating SARS CoV-2 infections
    Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • Thienopyrrole compounds
    Patent number: 11661431
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • Solid forms of a Cot inhibitor compound
    Patent number: 11655237
    Abstract: Disclosed are solid forms of a Cot (cancer Osaka thyroid) inhibitor and corresponding methods of preparation thereof, wherein the Cot inhibitor has the following formula:
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Kassibla E. Dempah, Bing Shi
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 11655285
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Nucleoside phosphoramidate prodrugs
    Patent number: 11642361
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Antibodies to matrix metalloproteinase 9
    Patent number: 11634505
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: April 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230102927
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: March 30, 2023
    Applicants: Gilead Sciences, Inc., Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Methods of preparing 1?-cyano nucleosides
    Patent number: 11613553
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A. J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • Substituted pyridotriazine compounds and uses thereof
    Patent number: 11613546
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwälder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 11597759
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 7, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
    Patent number: 11597742
    Abstract: The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: March 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Katrien Brak, Ernest A. Carra, Lars V. Heumann, Nate Larson
  • Blister pack packaging blank
    Patent number: D979401
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: February 28, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Trevor Zimmermann, Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot
  • Blister pack
    Patent number: D985397
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: May 9, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot
  • Blister pack
    Patent number: D985398
    Type: Grant
    Filed: November 10, 2022
    Date of Patent: May 9, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot